# Type 2 Diabetic Patients Maintained on Statin Therapy

Study · id `cardio:ct-nct03784703` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03784703](<https://clinicaltrials.gov/study/NCT03784703>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03784703

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT03784703. Randomized; double masking; primary purpose prevention. Start 2018-01-01 (actual); primary completion 2020-01-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT03784703, source copy `cardio:ctgov-nct03784703-2021-01-05`, retrieved 2026-10-26)
- Started: 2018-01-01 (actual) (ClinicalTrials.gov record NCT03784703, source copy `cardio:ctgov-nct03784703-2021-01-05`, retrieved 2026-10-26)
- Primary completion: 2020-01-30 (actual) (ClinicalTrials.gov record NCT03784703, source copy `cardio:ctgov-nct03784703-2021-01-05`, retrieved 2026-10-26)
- Completion: 2020-01-31 (actual) (ClinicalTrials.gov record NCT03784703, source copy `cardio:ctgov-nct03784703-2021-01-05`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT03784703, source copy `cardio:ctgov-nct03784703-2021-01-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03784703-2021-01-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Type 2 Diabetic Patients Maintained on Statin Therapy
- Condition: Dyslipidemia Associated With Type II Diabetes Mellitus
- Intervention (Drug): Atorvastatin 40 Mg Oral Tablet
- Intervention (Drug): Rosuvastatin 10 Mg Oral Tablet
- Lead sponsor: Damanhour University
- Lead sponsor class: OTHER
- Collaborator: Tanta University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Damanhour University (`cardio:org-damanhour-university`)
- Registry lists this organization as a collaborator: Tanta University (`cardio:org-tanta-university`)

## Provenance

Content hash: 89db4d0ccb012af58e7b7cac68179983cf1cdb65642da899d5fa71744572b8d1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
